Thursday, September 19, 2019

Evidence underpinning approval of new cancer drugs raises questions

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, which indicates that treatment effects might have been exaggerated, concludes a new study.

from Latest Science News -- ScienceDaily https://ift.tt/31A1EwW
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

They fled the flames—now jaguars rule a wetland refuge

After devastating wildfires scorched the Brazilian Pantanal, an unexpected phenomenon unfolded—more jaguars began arriving at a remote wetla...